Literature DB >> 11561688

Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes.

T Natsume1, T Nakamura, Y Koh, M Kobayashi, N Saijo, K Nishio.   

Abstract

Clinical use of TZT-1027, a microtubule-interfering agent that inhibits the polymerization of tubulin, is expected because of its potent effects on solid tumors. TZT-1027 is thought to act directly on cellular microtubules, and arrest cell mitosis, however, the molecular mechanisms of the microtubule damage by TZT-1027 have not been fully identified. To investigate the possible novel mechanisms of action of TZT-1027, we used the cDNA macroarray technique to examine its effect on the expression of hundreds of tightly transcriptionally controlled genes. We used two cell lines, one was human non-small cell lung carcinoma PC-14 cells as a model for cancer cells, and the other was human astrocytes as a model for normal neuronal cells, because the dose-limiting-factor of microtubule-interfering agents is mainly peripheral neurotoxicity. mRNAs prepared from the PC-14 and astrocyte cell lines treated with TZT-1027 were compared with 588 genes spotted onto the filter, and which gene groups TZT-1027 modulated between the two cell lines was investigated. TZT-1027 exposure modulated expression of a variety of genes including the genes encoding cell-cycle and growth regulators, receptors, angiogenesis and invasion regulators, rho family small GTPases and their regulators and growth factors and cytokines. However, the way of gene regulation by TZT-1027 exposure was different between PC-14 cells and astrocytes. Genes up-regulated in both PC-14 cells and astrocytes were those for RAR-epsilon, TNFR 1 and 2 and so on. Specifically altered genes in PC-14 cells, such as the genes coding for cytokeratin 8, XPG, fau and the genes regulated only in PC-14 cells may be involved in the antitumor activity of TZT-1027. On the other hand, growth factor receptor precursors was upregulated specifically in astrocytes by TZT-1027 and this gene regulation only in astrocytes may be candidates related with neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561688     DOI: 10.1023/a:1010605625538

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  13 in total

1.  Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent.

Authors:  J Watanabe; T Natsume; N Fujio; K Miyasaka; M Kobayashi
Journal:  Apoptosis       Date:  2000-10       Impact factor: 4.677

2.  Involvement of microtubules in the control of adhesion-dependent signal transduction.

Authors:  A Bershadsky; A Chausovsky; E Becker; A Lyubimova; B Geiger
Journal:  Curr Biol       Date:  1996-10-01       Impact factor: 10.834

Review 3.  Genomics and array technology.

Authors:  J L DeRisi; V R Iyer
Journal:  Curr Opin Oncol       Date:  1999-01       Impact factor: 3.645

4.  Microtubule disruption induces the formation of actin stress fibers and focal adhesions in cultured cells: possible involvement of the rho signal cascade.

Authors:  T Enomoto
Journal:  Cell Struct Funct       Date:  1996-10       Impact factor: 2.212

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Bcl2 is the guardian of microtubule integrity.

Authors:  S Haldar; A Basu; C M Croce
Journal:  Cancer Res       Date:  1997-01-15       Impact factor: 12.701

7.  Use of a cDNA microarray to analyse gene expression patterns in human cancer.

Authors:  J DeRisi; L Penland; P O Brown; M L Bittner; P S Meltzer; M Ray; Y Chen; Y A Su; J M Trent
Journal:  Nat Genet       Date:  1996-12       Impact factor: 38.330

8.  NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants.

Authors:  K Hayakawa; T Itoh; H Niwa; T Mutoh; G Sobue
Journal:  Brain Res       Date:  1998-06-01       Impact factor: 3.252

9.  Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

Authors:  M Kobayashi; T Natsume; S Tamaoki; J Watanabe; H Asano; T Mikami; K Miyasaka; K Miyazaki; M Gondo; K Sakakibara; S Tsukagoshi
Journal:  Jpn J Cancer Res       Date:  1997-03

10.  Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.

Authors:  T Natsume; J Watanabe; S Tamaoki; N Fujio; K Miyasaka; M Kobayashi
Journal:  Jpn J Cancer Res       Date:  2000-07
View more
  2 in total

1.  A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.

Authors:  Ralph P Mason; Dawen Zhao; Li Liu; Mary Lynn Trawick; Kevin G Pinney
Journal:  Integr Biol (Camb)       Date:  2011-02-14       Impact factor: 2.192

2.  Differential gene expression in auristatin PHE-treated Cryptococcus neoformans.

Authors:  Tanja Woyke; Michael E Berens; Dominique B Hoelzinger; George R Pettit; Günther Winkelmann; Robin K Pettit
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.